Arkolith/Insider Trading/CRVS/Form 4

Lea Leiv

Chief Financial OfficerCorvus Pharmaceuticals, Inc. (CRVS) · full profile →Form 4 · filed Dec 15, 2022
Net Buying
Open-Market Buys
$26K
Open-Market Sells
$0
Net Open-Market Flow
$26K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 14, 2022Buy(P)4K$0.84$3K133K
Dec 13, 2022Buy(P)30K$0.74$22K129K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001567619-22-021651) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML